Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nyotran vs Amphotericin B for Febrile Neutropenia
NCT00002742Phase 3Completed
- Sponsor
- Aronex Pharmaceuticals, Inc.
- Start
- Jan 1996
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Nyotran in febrile neutropenia (FN) (2 arms), sponsored by Aronex Pharmaceuticals, Inc. Primary endpoint: Efficacy of liposomal nystatin vs standard amphotericin B. Started Jan 1996; status: completed.
02
Drugs
Nyotran
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00002742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002742.